ArticleFrontiers in physiology2026
Direct aldosterone stimulation of skeletal muscle fibroblasts changes gene expression and differentially affects fibroblast functions from normal and diseased muscles.
Article in Frontiers in physiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Introduction: Fibroblasts are critical for stabilizing skeletal muscle and facilitating wound healing after injury but become overactivated and lead to fibrotic replacement of muscle tissue in chronic degenerative diseases such as Duchenne muscular dystrophy (DMD). We have previously shown that the mineralocorticoid receptor (MR) is present in skeletal muscle and MR antagonist drugs reduce fibrosis and chronic inflammation in dystrophic mouse models. Indirect MR signaling from other cell types in the muscle microenvironment affects fibroblast gene expression and function. However, the direct effects of MR activation of skeletal muscle fibroblasts are unknown. Methods: To determine whether direct stimulation with the endogenous MR agonist aldosterone changes gene expression in skeletal muscle fibroblasts, we performed RNA sequencing comparing fibroblasts isolated from neonatal wild-type skeletal muscles treated with aldosterone or vehicle. To further investigate the effects of aldosterone treatment of fibroblasts in skeletal muscle health and disease, we then performed Results: Treatment with aldosterone leads to differential expression of 492 genes in fibroblasts isolated from neonatal wild-type mouse muscles. Protein levels of differentially expressed genes Fkbp5, p57 and c-Fos were also increased by direct aldosterone stimulation of fibroblasts from both wild-type and dystrophic muscles. Surprisingly, cultured fibroblasts from both neonatal wild-type and dystrophic muscles retain a higher proliferation rate compared to adult muscle fibroblasts. Direct aldosterone treatment represses proliferation and slows scratch-wound closure kinetics only in fibroblasts isolated from adult dystrophic skeletal muscle. Discussion: This study shows that aldosterone treatment of skeletal muscle fibroblasts alters gene expression. However, fibroblasts from adult dystrophic muscle appear most sensitive to gene expression changes after short-term aldosterone treatment. These data suggest that MR signaling in the skeletal muscle microenvironment may differentially affect fibroblasts in wound healing and in chronic fibrotic diseases such as muscular dystrophies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.